SPG7 and AFG3L are *m*-AAA proteases that form homo-oligomeric complexes and perform essential functions in mitochondrial quality control (Quirós et al., [@B16]). Mutations of the SPG7 and AFG3L genes cause an autosomal recessive form of hereditary spastic paraplegia (Casari et al., [@B7]) and spinocerebellar ataxia (Atorino et al., [@B2]; Di Bella et al., [@B9]), respectively, as well as other neurological syndromes (Pierson et al., [@B14]). Mitochondrial dysfunction plays a fundamental role in disease onset, as suggested by decreased activity of respiratory complex I and increased sensitivity to reactive oxygen species (Atorino et al., [@B2]). König et al. now show that *m*-AAA proteases assist in the correct formation of the mitochondrial Ca^2+^ uniporter (MCU) complex by regulating the levels of its essential subunit EMRE (König et al., [@B11]). The study provides a potential mechanistic link between *m*-AAA protease dysfunction, deregulation of Ca^2+^ homeostasis and opening of the permeability transition pore (PTP), a high conductance channel that requires matrix Ca^2+^ and is stimulated by oxidative stress (Bernardi et al., [@B6]). The suggestion that SPG7 is part of the PTP (Shanmughapriya et al., [@B20]) is seriously questioned by the findings of the article covered in this editorial, supporting the view outlined in a previous commentary (Bernardi and Forte, [@B5]).

In energized mitochondria the Ca^2+^ electrochemical gradient drives Ca^2+^ uptake through the MCU (Baughman et al., [@B4]; De Stefani et al., [@B8]). MCU function is affected by the regulatory subunits MICU1 (Perocchi et al., [@B13]), MICU2 (Plovanich et al., [@B15]), the MCU inhibitory paralog MCUb (Raffaello et al., [@B17]) and EMRE (Sancak et al., [@B18]), a sensor for matrix Ca^2+^ and a critical gatekeeper for the MCU (Vais et al., [@B21]). In the absence of EMRE (which faces the matrix) MCU currents are no longer inhibited by matrix Ca^2+^ (which would normally limit its accumulation) resulting in enhanced mitochondrial Ca^2+^ uptake and elevation of matrix \[Ca^2+^\] (Vais et al., [@B21]). It was already known (and somewhat puzzling) that EMRE-dependent regulation of MCU channel activity requires both MICU1 and MICU2, which are localized on the opposite side of the inner membrane and face the intermembrane space (Vais et al., [@B21]). The results of König et al. bear on this issue with the novel finding that EMRE is a substrate of *m*-AAA proteases in the intermembrane space before its import and incorporation into the MICU1-MICU2 complex during the dynamic processes that ultimately generate the complete, regulated MCU complex. In the absence of adequate *m*-AAA protease activity, the excess EMRE associates with the MCU in a complex that lacks MICU1 and MICU2 (König et al., [@B11]). This unprocessed, unregulated MCU-EMRE complex would not be inhibited by matrix Ca^2+^ and thus mediate excessive mitochondrial Ca^2+^ uptake, leading to opening of the PTP and to all its detrimental consequences linked to deregulation of Ca^2+^ homeostasis and ATP depletion (Bernardi et al., [@B6]). Consistent with this picture, mitochondria from HeLa cells and from mice lacking SPG7 and/or AFG3L displayed increased sensitivity to Ca^2+^-induced PTP opening (König et al., [@B11]), as measured with the Ca^2+^ retention capacity (CRC) assay, i.e., the amount of Ca^2+^ needed to trigger pore opening. This is the opposite of what was reported by Shanmughapriya et al. who carried out a phenotypic screen of the CRC in permeabilized cells after inactivation of a variety of genes. According to this report, SPG7 downregulation *desensitized* the PTP by rendering it less sensitive to Ca^2+^ (Shanmughapriya et al., [@B20]). In contrast, König et al. find that depletion of SPG7 *facilitated* PTP opening under all conditions tested (König et al., [@B11]). Irrespective of the basis for this discrepancy, which might depend on complementation by homo-oligomeric AFG3L2 and will need further investigation, the predictions of the two sets of opposing findings can be matched against the known hallmarks of diseases linked to mutations of *m*-AAA proteases.

Mitochondrial dysfunction is of pathogenic relevance to neurodegenerative disorders due to mutations of *m*-AAA proteases. This is clearly indicated by the presence of abnormal, often swollen mitochondria (Casari et al., [@B7]; Atorino et al., [@B2]; Ferreirinha et al., [@B10]; Di Bella et al., [@B9]; Almajan et al., [@B1]), which is the expected outcome of PTP opening (Bernardi et al., [@B6]). The second element is derangement of Ca^2+^ homeostasis since both downregulation of the glutamate receptor, which mediates Ca^2+^-dependent PTP opening (Schinder et al., [@B19]), and decrease of cytosolic \[Ca^2+^\] suppressed ataxia in an AFG3L2-deficent mouse (Maltecca et al., [@B12]). Thus, the pathological alterations are best explained by PTP sensitization (König et al., [@B11]) rather than by PTP inhibition (Shanmughapriya et al., [@B20]). It should be noted that decreased activity of respiratory complex I and increased reactive oxygen species (Atorino et al., [@B2]) can cause sensitization to PTP opening even if the increase of mitochondrial \[Ca^2+^\] is not large (e.g., Figure 6C). *m*-AAA proteases possess only 2 hydrophobic regions (Casari et al., [@B7]; Banfi et al., [@B3]) and are therefore unlikely to form high-conductance channels. We think that this missing piece of evidence, which is essential to substantiate the claim that SPG7 is a constituent of the PTP (Shanmughapriya et al., [@B20]), should be provided before this hypothesis can be considered further. For the time being we believe that an indirect, PTP inducing effect of defective *m*-AAA proteases is the most plausible explanation for the pathogenesis of neurological diseases due to mutations in their genes. Formation of deregulated MCU complexes provides a provocative but testable mechanism for the increased probability of PTP opening.
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